

## II. AMENDMENTS TO THE CLAIMS


Please withdraw claims 1-140, 142, and 143 without prejudice.

Please amend the claims as follows:

Claims 1-140 (Withdrawn)


a<sup>1</sup>  
Claim 141 (Newly Amended) A method for treating or preventing a neoplasia disorder in a mammal in need of such treatment or prevention, which method comprises administering to said mammal a therapeutically-effective amount of a combination of celecoxib-cyclooxygenase 2 inhibitor and (3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine, an integrin antagonist, wherein said integrin antagonist is selected from compounds, and their pharmaceutically acceptable salts thereof, of the group consisting of:

1)-



(3R)-N-[[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;


2)-



~~(3R)-N-[[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~


3)

a<sup>1</sup>  
cont




~~(3R)-N-[[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~

4)




~~(3R)-N-[[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy)-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~

5)




~~(3R)-N-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~


6)




(3R)-N-[3-((aminoiminomethyl)amino)benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine;



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine;




(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-L-alanine;




~~(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-D-alanine,~~

10)




~~(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,~~

11)




~~b-[3-[[[3-[[4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]sulfonyl]amino]phenyl]-3,5-difluorobenzene]propanoic acid,~~

12)




~~3,5-difluoro-b-[3-[[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]methyl]phenyl]benzene]propanoic acid,~~

13)




14)

*A1  
Crist*




~~(2E)-3-[3-ethyl-4-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]phenyl]-2-propenoic acid,~~

15)




~~(2E)-3-[3-[2-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]-2-oxoethoxy]phenyl]-2-propenoic acid,~~

16)




~~(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid,~~


17)




- 18) (2S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid,




- 19) (2S)-2,3,4,5-tetrahydro-4-methyl-7-[[[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid,




- 20) (bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid,




21)



22)




23)




24) — Vitaxin antibody(Ixsys),

25) — Merck KGaA EMD 121974, cyclo[RGDfN(Me)V],


26)




27)




28)




29)




30)




31)



32)




33)




34)

1  
a  
cont







35)




36)




37)




38)




39)




40)




41)



42)




43)



Claims 142-143 (Withdrawn)


Claim 144 (Newly Amended) A combination comprising celecoxiba-cyclooxygenase 2-inhibitor and (3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine, an integrin antagonist, wherein said integrin antagonist is selected from compounds, and their pharmaceutically acceptable salts thereof, of the group consisting of:

1)-




(3R)-N-[[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine,

2)-




(3R)-N-[[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine,

3)-




~~(3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~

4)




~~(3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~

5)




~~(3R)-N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~

6)




~~(3R)-N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~

7)




~~(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine,~~

8)




~~(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-L-alanine,~~

9)



~~(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-L-alanine,~~


10)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-L-alanine;


11)

1  
Cont




L-3-[[[3-[[[4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]sulfonyl]amino]phenyl]-3,5-difluorobenzene]propanoic acid;

12)




3,5-difluoro-L-3-[[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]methyl]phenyl]benzene]propanoic acid;

13)




14)




~~(2E) 3-[3-ethyl-4-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]phenyl]-2-propenoic acid,~~

15)




~~(2E) 3-[3-[2-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]-2-oxoethoxy]phenyl]-2-propenoic acid,~~

16)




~~(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid,~~

17)




~~(2S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid,~~

18)




~~(2S)-2,3,4,5-tetrahydro-4-methyl-7-[[[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid,~~

19)




~~(bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid,~~


20)




21)



22)



23)







24) ~~Vitaxin antibody(Ixsys),~~

25) ~~Merck KGaA EMD 121974, cyclo[RGDf N(Me)V ],~~


26)




27)




28)



29)




30)




5

31)




5

32)




5

33)



5


34)




5

35)


1  
a  
cont




36)




37)



38)




39)




40)

1  
a  
cont



5


41)



5


*Contd*

42)



, and

43)



7